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Background: International travel is an important risk factor for colonization with extended-spectrum 
beta-lactamase-producing Enterobacteriaceae (ESBL-PE). Antimicrobial use during travel likely amplifies 
this risk, yet to what extent, and whether it varies by antimicrobial class, has not been established. 
Methods: We conducted a systematic review that included prospective cohorts reporting both receipt 
of systemic antimicrobials and acquired ESBL-PE isolated from stool or rectum during international 
travel. We performed a random effects meta-analysis to estimate odds of acquiring ESBL-PE due to 
antimicrobials during travel, overall and by antimicrobial class. Results: Fifteen studies were included. 
The study population was mainly female travellers from high income countries recruited primarily from 
travel clinics. Participants travelled most frequently to Asia and Africa with 10% reporting antimicrobial 
use during travel. The combined odds ratio (OR) for ESBL-PE acquisition during travel was 2.37 for 
antimicrobial use overall (95% confidence interval [CI], 1.69 to 3.33), but there was substantial 
heterogeneity between studies. Fluoroquinolones were the antibiotic class associated with the highest 
combined OR of ESBL-PE acquisition, compared to no antimicrobial use (OR 4.68, 95% CI, 2.34 to 9.37). 
Conclusions: The risk of ESBL-PE colonization during travel is increased substantially with exposure to 
antimicrobials, especially fluoroquinolones. While a small proportion of colonized individuals will 
develop a resistant infection, there remains the potential for onward spread among returning travellers. 




  Research in context 
Evidence before this study 
Antimicrobial resistance (AMR) among bacteria that commonly cause human infection is of 
increasing public health concern. International travel has recently been associated with 
colonization with Extended-Spectrum Beta-Lactamase Producing-Enterobacteriaceae (ESBL-PE), 
increasing the spread of drug resistance among these important pathogens. We searched Pubmed, 
Embase, MEDLINE, Web of Science, SCOPUS, and the Cochrane Library for prospective cohort 
studies  published between January 2000 and June 2018, reporting on acquisition of ESBL-PE 
among travellers, which reported on antimicrobial use during travel. 15 studies were included, 
which were at moderate risk of bias.  The pooled odds ratio for acquisition of ESBL-PE during travel 
was 2.37 among antimicrobial users, compared to non-users (95% CI, 1.69 to 3.33). The magnitude 
of this association was stronger among travellers reporting fluoroquinolone use (OR 4.68, 95% CI 
2.34 to 9.37). 
Added value of this study 
This is the first study to quantify the association between antimicrobial use during travel, overall 
and by specific antimicrobial class, with ESBL-PE acquisition across broad populations of travellers 
and destination countries.  
Implications of all the available evidence 
Further study into the mechanisms by which antimicrobials, such as fluoroquinolones, contribute 
to AMR may identify protective measures. Meanwhile, antimicrobial use during travel for 
prevention or treatment of mild-to-moderate traveller’s diarrhea should not be recommended 




In 2014 the World Health Organization declared that a “post-antibiotic era” is within sight if 
urgent action was not taken1. At the forefront of this growing public health threat is drug resistance in 
Enterobacteriaceae, a family of gram-negative bacteria which make up a large part of normal human gut 
flora.  Extended-spectrum beta-lactamase (ESBL) enzymes are an important cause of increasing bacterial 
resistance globally2,3 with ESBL-producing Enterobacteriaceae (ESBL-PE) colonizing humans either de 
novo or through fecal-oral transmission4. ESBL enzymes render all penicillin, monobactam and 
expanded-spectrum cephalosporin antimicrobials2,5 ineffective. Carriers of ESBL-PE are usually 
asymptomatic4, but are at risk to develop clinical infection due to these organisms, resulting in increased 
cost, morbidity, and mortality compared to infections due to  drug-susceptible Enterobacteriaceae4,6,7.  
The prevalence of ESBL-PE varies worldwide and by epidemiologic setting1,3,4. For example, the 
frequency of ESBL-PE is relatively low in North America and Europe1, and comparatively much higher in 
many lower income countries, especially in South Asia4. Accordingly, observational studies have 
established a strong association between asymptomatic ESBL-PE acquisition and international travel8–23. 
The risk of acquiring carriage with ESBL-PE is over 20% with any international travel, and higher with 
travel to areas of particularly high prevalence such as South Asia15,24. Few healthy travellers colonized 
with ESBL-PE will develop infection,25,26 however, an estimated 12% will transmit these bacteria to other 
household members9.   
Antimicrobial use has been inconsistently reported as an independent risk factor for ESBL-PE 
acquisition among international travellers15,24. Estimates around the degree of risk antimicrobial use 




We conducted a systematic review and meta-analysis to determine the extent to which receipt 
of antimicrobials during travel increase the odds of faecal carriage with ESBL-PE compared to those that 
do not receive antimicrobials, as well as how much these odds vary between antimicrobial classes. 
METHODS 
We included only prospective cohort studies, related to travel across an international boundary, 
reporting screening for faecal Enterobacteriaceae carriage (in asymptomatic participants) both prior to 
and after travel, in our review. Studies must have presented phenotypic antimicrobial susceptibility data 
(or molecular equivalent) which is adequate to ascertain ESBL-PE presence or absence, and were 
excluded if ESBL-PE acquisition status by presence or absence of receipt of systemic antimicrobials taken 
during travel was not reported.   
We searched Embase, MEDLINE, Web of Science, SCOPUS, Cochrane Library, and PubMed for 
studies published in peer-reviewed English journals from January 2000 to June 2018 (Box 1). The 
reference lists, and citations of included studies, were inspected to identify further potentially eligible 
studies. Citations were entered and housed in CovidenceTM, and abstracts were screened for eligibility 
by 2 independent reviewers (TW, SK). Studies selected for full text review were read in full to ascertain 
whether inclusion criteria were met and selected for data extraction as appropriate. Conflicts were 
resolved by consensus by 2 authors (TW, SK). Each included study was assessed using tools for assessing 
bias in observational studies as recommended in the STROBE statement27 and modified to suit the study 
design.  
Data were extracted by a single author (TW) from each included article and exported to Stata 13 
for analysis. Data gathered included details on study population and travel characteristics, potential 
confounders, antimicrobials taken during travel, method of determining ESBL-PE pre- and post-travel, 
the prevalence of ESBL-PE pre- and post-travel, and study quality metrics. Odds ratios for acquisition of 
ESBL-PE, by presence or absence of antimicrobial exposure during travel, with 95% confidence intervals 
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of all included studies were displayed as a Forrest plot. Data were visually inspected for heterogeneity of 
results; Cochrane’s Q and I2 were calculated to quantify this heterogeneity. As there was substantial 
evidence of heterogeneity, a random effects model of meta-analysis, representing the average odds 
ratio of ESBL-PE due to antimicrobial exposure during travel, was built. For the secondary analysis, a 
random effects meta-analysis was undertaken of rates of ESBL-PE acquisition by antimicrobial class 
(beta-lactam, fluoroquinolone, macrolide or tetracycline) received during travel, compared to no 
antimicrobial receipt (the baseline group).  
All antimicrobials including doxycycline were included in the primary analysis, however, 
doxycycline was excluded from this analysis in 2 studies, as it was counted as an antimalarial drug and 
the data grouping did not permit analysis compared no antibiotic receipt for these studies. We therefore 
also performed a sensitivity analysis by comparing the random effects meta-analysis which excluded 
doxycycline as an antimicrobial to the primary analysis which included. For all studies, we plotted effect 
size (log OR for ESBL-PE acquisition during travel related antimicrobial exposure) against log standard 
error of each study to create a funnel plot. The quality of the studies was assessed using the modified 
STROBE27 tool.  
Studies were excluded from the secondary analysis if no information was available on 
proportion of ESBL-PE acquisition stratified by antimicrobial class. Authors of the 10 studies missing 
crucial data for our secondary analysis were contacted to obtain it; 6 replies were received. 
RESULTS 
The search strategy identified 5323 journal articles in published peer-reviewed journals (Figure 
1). 1893 duplicates were identified and removed, leaving 3430 study titles and abstracts, of which 3372 
were excluded on screening. 58 published manuscripts were reviewed in full and 15 studies were 
included for the systematic review.  
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The 15 included prospective cohort studies were published from 2010 to 2017, and enrolled 
travellers from 2007 to 20158–14,16–23. The studies included 5283 participants (median, 205; range, 58 to 
1965) and in all but 2 instances were conducted in Northern or Western Europe (Supplementary Table 
1). The median age of participants varied substantially, but in all studies, fewer than 50% were male. 13 
studies used a phenotypic approach for determination of ESBL-PE status (with polymerase chain 
reaction [PCR] for confirmation) whereas 2 studies adopted a molecular approach, using PCR to identify 
the gene encoding ESBL production within Enterobacteriaceae, blaCTX-M, without culture14,20. 
Asia, including South Asia region to which travel carries the highest risk of ESBL-PE acquisition, 
was the most common region travelled to, followed by Africa (Table 1a). Median travel time ranged 
from 14-21 days in most studies, and the median percentage of travellers reporting diarrhea or 
gastroenteritis was 38% (range: 12 to 69%). In total, 550 participants (10% of the total) reported 
systemic antimicrobial usage (range by study: 4-49%). The most common indications were lower 
respiratory tract infection and traveller’s diarrhea. Of participants reporting a specific class of 
antimicrobial use, beta-lactams (30%), fluoroquinolones (25%), and doxycycline (20%) were more 
common than macrolides (8%). A total of 1748 participants acquired ESBL-PE carriage during travel; this 
also varied significantly by study, from 9% of to 69% (median 31%).  
All studies used reliable laboratory phenotypic or genotypic methodology; however, all 
enrolment was from non-random samples of travellers. All but 2 studies10,23 did not exclude co-travellers 
(groups of travellers) from enrolment. The exposure of interest, antimicrobial use during travel, was 
ascertained via post-travel questionnaire in all studies. While important potential confounding was 
reported in all studies, duration of antimicrobial usage was not reported by any. 4 studies14,16,23,28 
provided no information about losses to follow-up; for the remainder, the median number lost to 
follow-up was low (7.5%). 
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The point estimates of the odds ratio (OR) for ESBL-PE acquisition by any or no systemic 
antimicrobial exposure varied between 0.53 to 8.05 for individual studies (Table 1b).  
We included all studies in a random effects meta-analysis (Figure 2). Our primary analysis found 
that the combined OR for effect of all antimicrobials on ESBL-PE acquisition was 2.37 (95% CI 1.69 to 
3.33, p < 0.01, I2=57%, which indicates strong evidence for heterogeneity). A sensitivity analysis 
excluding doxycycline (all but 2 studies21,22), yielded very similar results (OR 2.48, 95% CI 1.76 to 3.50, 
p<0.01, I2 54%). Visual inspection of the funnel plot (Supplementary Figure 1) found no strong evidence 
of bias across the studies. 
Excluding 4 studies with no information on ESBL-PE acquisition by class of antimicrobial 
received13,14,17,22, we found fluoroquinolone exposure was associated with a combined OR of 4.68 
compared to no antibiotics (95% CI, 2.34 to 9.37), tetracyclines were associated a combined OR of 1.68 
(95% CI, 1.03 to 2.72) (Table 2). On average, there was no evidence of a combined increased odds of 
ESBL-PE acquisition by exposure to beta-lactams or macrolides. 
DISCUSSION 
International travel has been previously identified as an important risk factor for both 
colonization and infection with ESBL-PE15,25,26, and likely plays an important role in the spread of ESBL-PE 
within high income countries. However, the risk has not been systematically quantified. Our systematic 
review and meta-analysis found that systemic antimicrobial use during travel was associated with an 
odds ratio of 2.37 for acquiring ESBL-PE. Given a baseline risk of ESBL-PE acquisition of 20% or higher 
among international travellers9,15, and antimicrobial use in an average of 10% of such travellers, the 
burden of this additional risk is substantial. Our analysis found that fluoroquinolones and tetracyclines 
(doxycycline) were associated with the increased risk of ESBL-PE acquisition, with a combined OR of 4.68 
and 1.68 respectively. 
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While antimicrobial use is widely recognized to be a major driver of antimicrobial resistance 
(AMR), quantifying its impact can be challenging. Ecologic data comparing antimicrobial consumption in 
the community and hospital has been positively correlated to AMR (from hospital bacterial isolates) 
over time and across countries29,30.  Previous systematic reviews15,24 have examined the risk of ESBL-PE 
acquisition in travellers. Unlike the previous studies, we used a meta-analysis to independently estimate 
the degree to which antimicrobial usage during travel increases the odds of ESBL-PE acquisition across 
populations of international travellers from high income countries, and to compare specific classes of 
antimicrobials. Doxycycline has not previously been associated with an increased risk of MRE 
acquisition24, possibly due to lower numbers exposed and a less strong association compared to 
fluoroquinolones. 
There exist several pathways through which antimicrobial use might cause an increase in 
acquisition in ESBL-PE during travel.  First, selection pressure due to antimicrobial effect on more drug-
sensitive strains of Enterobacteriaceae can select for increased resistance within an individual. This 
selection could be due to antimicrobials taken in response to disease causing Enterobacteriaceae or, 
substantially more likely, due to the by-stander effect whereby non-invasive bacteria are exposed to 
antimicrobials31. This pathway would predict beta-lactams might be causatively associated with 
increased risk of ESBL-PE acquisition, which we did not observe; additionally, ESBL-PE are commonly co-
resistant to other antibiotic classes such as fluoroquinolones3. An alternate pathway involves the ability 
of the healthy gut microbiota to prevent expansion of potential pathogens including resistant bacteria 
such as ESBL-PE, a phenomenon termed ‘colonization resistance’32. Disruption of microbial composition 
due to exposure to antimicrobials decreases colonization resistance33, reducing the normally protective 
capabilities of an intestine with fully diverse and intact microbial composition. Proposed mechanisms for 
the normal flora-mediated resistance to colonization include direct microbial competition for nutrients, 
production of bacteriocin peptides which inhibit the growth of specific types of bacteria, and more 
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complex indirect mechanisms involving interaction between bacterial communities to help maintain 
host immune responses33,34. Fluoroquinolones, in contrast with narrower spectrum antimicrobials, have 
a relatively large impact on the composition of normal gut microbiota composition due to their broad 
spectrum of activity and high local concentrations achieved35. In addition to high rates of co-resistance 
to fluoroquinolones among ESBL-PE2,3, this may in part explain their large effect on ESBL-PE acquisition 
seen in this study. 
An estimated 30% of outpatient antimicrobial prescriptions in the US are considered 
inappropriate36. It is likely that inappropriate antimicrobial use is even higher in lower income countries, 
where most consumption is attributable to over-the-counter use. Moreover, travellers from high income 
countries to tropical settings have historically been counselled to bring antimicrobials, including 
commonly fluoroquinolones, as preventative or abortive treatment of diarrhea37,38. While more recent 
guidelines have scaled back the uniform recommendation of traveller antimicrobial use, partly in 
response to increased recognition of the risk of faecal drug resistant carriage, some still suggest 
antimicrobials may be used as therapy for cases of moderate or severe traveller’s diarrhea (TD)37. 
Moreover, antibiotics are not commonly prescribed pre-travel as ‘stand-by’ therapy, a practice which 
increases their inappropriate use in milder TD cases38.  This study supports calls39 to avoid unnecessary 
antimicrobial consumption during travel, including those taken for prevention or treatment of mild-to-
moderate severity TD in healthy travellers. Stand-by antibiotic prescriptions before travel should be 
limited to those who are at increased risk (such as immunocompromised travellers).  When they cannot 
be avoided altogether, our results suggest using alternative antimicrobials to fluoroquinolones, in view 
of the higher odds of ESBL-PE acquisition associated with this class.  
This meta-analysis included only prospective cohort studies with robust microbiologic 
assessments of ESBL-PE carriage. The strength of excluding ESBL-PE carriers pre-travel is that any ESBL-
PE carrier can be shown to have acquired the resistant bacteria during travel, which can in turn may 
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generally be attributed to exposures and behaviours taken during the trip. Additionally, while each study 
recruited travellers from a single country in North America, Europe or Australia, the aggregate analysis 
supports a broader generalization of healthy tourists from high income regions of the world travelling 
internationally to tropical, lower income countries. 
However, there are limitations to the analysis. First, antimicrobial effect on ESBL-PE acquisition 
may be mediated partially through an indication of gastroenteritis, which is both an independent risk 
factor for ESBL-PE acquisition9,17 and also a condition for which fluoroquinolones are commonly 
recommended for international travellers40. That is, there is a question about the direction of 
association between fluroquinolone use and carriage of ESBL-PE. While an analysis accounting for 
antimicrobial indication was not possible in this review, several prospective studies have adjusted for 
diarrhea or gastroenteritis as a confounder9–11,13,17.  In these studies, a strong and significant effect of 
antimicrobial on increased rates of ESBL-PE acquisition during travel persisted. Similarly, many studies 
documented the presence or absence of proven confounders in individual participants, including age, 
sex, length of travel, and travel destination which are potentially related to both rates of antimicrobial 
use, and risk of ESBL-PE acquisition. However, individual studies including the single largest study 
included in this review9 were able to account for these variables in the analysis, and found a persistent 
effect on ESBL-PE acquisition related to antimicrobial exposure during travel. 
Additionally, the designs of the included studies present potential limitations. For instance, 
losses to follow-up after travel, while not large where provided, were not reported in 4 studies. 
Selection bias may occur if those lost had different rates of antimicrobial use and rates of ESBL-PE 
acquisition; however, it seems unlikely the magnitude of this effect would be large enough to 
substantially change the observed odds ratio. Participants in all studies were non-random volunteers 
from higher income countries which may limit generalizability of the results to travellers not attending 
such clinics or originating from lower income countries. Meanwhile, antimicrobial exposure was self-
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reported after travel, and data on antimicrobial class was limited to 11 studies, which might 
underestimate the effect of specific classes during travel on ESBL-PE acquisition. 
 
CONCLUSION 
The odds of acquiring ESBL-PE are substantially increased when antimicrobials are consumed during 
travel. This risk is shared unevenly among antimicrobial classes, with fluoroquinolones posing a 
substantial risk compared to others. Incorporation of this analysis in decisions and guidelines addressing 
whether to use antimicrobials during travel will allow for a better realization of the true risks versus 
benefits. We call for further study into the mechanisms by which antimicrobials, and in particular 
fluoroquinolones, contribute to AMR, including indirect mechanisms mediated by disruption of the gut 
microbiome. This may identify fruitful protective factors which may ameliorate the effect of 
antimicrobials on AMR, which are needed. In the meantime, it seems prudent for travel health 
practitioners to avoid prescribing stand-by antibiotics for travellers who are not at increased risk, and to 
emphasize limiting the consumption of antimicrobials for these individuals to the treatment of severe 
cases of TD only. 
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BOX 1. DETAILED SEARCH STRATEGY USED IN PUBMED. 
PubMed 
(Enterobacteriaceae[MeSH Major Topic] OR (Enterobacteriaceae*[tiab] OR Gram negative bacteri*[tiab] OR E. coli [tiab]OR 
Escherischia*[tiab] OR Klebsiella*[tiab] OR Salmonella[tiab] OR Proteus[tiab] OR Enterobacter[tiab] OR Shigella[tiab] OR 
Yersinia[tiab] OR gut flora[tiab])) AND (Drug Resistance, Bacterial[MeSH Major Topic] OR (Drug resistan*[tiab] OR 
Extended-spectrum beta-lactamase[tiab] OR ESBL[tiab] OR Amp C[tiab] OR Carbapenemase*[tiab] OR CPE[tiab] OR 
CRE[tiab] OR Cephalosporinase[tiab] OR Penicillinase[tiab] OR beta-lactamase[tiab] OR CTX-M[tiab] OR 
((Cephalosporin[tiab] OR Cefepime[tiab] OR ceftriaxone[tiab] OR Cefotaxime[tiab] OR Ceftazidime[tiab] OR 
antibiotic*[tiab] OR antimicrob*[tiab]) AND (sensitivit*[tiab] OR susceptibil*[tiab] OR resistan*[tiab])))) AND (Travel[MeSH 
Major Topic] OR (Travel*[tiab] OR International[tiab] OR Trip[tiab] OR Voyage[tiab] OR Air Transport[tiab] OR Post-





Figure 1: Flowchart depicting studies screened, reviewed and finally included for systematic review. 
                                                                                                                         
  
5323 references identified by 
search strategy for screening 
3430 studies screened 
against title and abstract 
58 studies assessed for full-
text eligibility 
15 studies included 
1893 duplicates removed 
3372 studies irrelevant 
43 studies excluded 
   Wrong study design – 27    
   Wrong patient population – 8  
   Incomplete exposure data – 4  
   Previously published study   
population – 1  
   No participants exposed – 2  
   Wrong outcome – 1  
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Table 1a: Characteristics of travel for studies included for systematic review of the risk of acquiring Extended-
Spectrum Producing-Enterobacteriaceae after exposure to antimicrobials during travel. 
First Study 
Author 
Top 3 Regions Travelled to2 




Percentage of all travellers who: Top 2 Classes 
of Antimicrobials 







Angelin South Asia(40), SSA (39), Asia(8) 45 
(13-365) 




Asia (41), SSA (21), 











Blyth South/Central America (33), Asia 
& South Asia (27), Africa (27) 
12* 
(6-105) 
12 10 9 Tetracyclines 
(50), FQs (33%) 
Kantele SSA (45), Asia 
(25), South Asia (14) 
19 
(4-133) 
67 15 21 FQs (70), 
Macrolides (14) 
Kennedy Asia (49), Europe (16), 








(54), FQ (7) 
Kuenzli 
 















Middle East (100) 28 
(24-32) 




SSA (31), Asia (30), South/ 










(38), FQs (17) 
Ostholm- 
Balkhed 
Africa (34), Asia (26) 
South & Central America (13) 
16 
(4-119) 
42 9 30 NR 
Paltansing 
 













Reuland Asia & South Asia (56), Africa 
(22), South/Central America (18) 




Asia & South Asia (34), SSA (34), 












Tängdén Asia (30), SSA (24), Europe (15) 14 
(1-26) 




Asia (39), South Asia (35), 

















37 14 31 NR 
1Who provided both pre-travel and post-travel samples for analysis. 2Unless otherwise indicated, South Asia (including 
India, Pakistan, Nepal, Sri Lanka, and Bangladesh) included seperately from the rest of Asia, due to higher rates of ESBL-
PE. *Median is presented. ⱡInterquartile range is presented. Definitions: NR not reported, ESBL-PE Extended-spectrum 
beta-lactamase-produding Enterobacteriaceae, SSA Sub-Saharan Africa, FQ fluoroquinolone   
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Table 1b: Rates extended-spectrum beta-lactamase acquisition by antimicrobial exposure during travel, with crude 






ESBL-PE (% all 
participants) 
Number exposed to 
antibiotics who 
acquired ESBL-PE2 
(% of those exposed) 
Number not exposed 
to antibiotics who 
acquired ESBL-PE2 (% 
of those not exposed) 
Odds ratio for 
acquisition of ESBL-
PE by antibiotic 
exposure (95% CI) 
Angelin 35 (36) 20 (25) 30 (38) 0.53 (0.18, 1.62) 
Arcilla 633 (34) 132 (55) 553 (33) 2.56 (1.79, 3.66) 
Blyth 5 (9) 6 (33) 3 (6) 8.50 (1.09, 66.6) 
Kantele 90 (21) 66 (42) 62 (17) 3.53 (2.02, 6.18) 
Kennedy 50 (49) 28 (68) 31 (42) 2.93 (1.17, 7.33) 
Kuenzli 118 (69) 7 (71) 101 (69) 1.14 (0.21, 6.09) 
Leangapichart 73 (37) 107 (36) 35 (40) 0.83 (0.47, 1.49) 
Lübbert 58 (30) 24 (38) 15 (9) 6.08 (2.28, 16.23) 
Ostholm-Balkhed 68 (30) 20 (25) 15 (7) 4.24 (1.36, 13.28) 
Paltansing 113 (33) 19 (47) 104 (33) 1.86 (0.73, 4.72) 
Reuland 95 (23) 22 (50) 87 (22) 3.46 (1.45, 8.25) 
Ruppé 292 (51) 59 (73) 249 (48) 2.87 (1.58, 5.23) 
Tängdén 24 (24) 10 (30) 21 (23) 1.41 (0.33, 5.93) 
Vading 56 (24) 15 (67) 46 (29) 4.91 (1.59, 15.16) 
Von Wintersdorff 38 (31) 15 (40) 32 (30) 1.56 (0.51, 4.75) 
1Who provided both pre-travel and post-travel samples for analysis. 




Figure 2: Forest plot of random effects model, for odds ratio (OR) of extended-spectrum beta-lactamase-producing 
Enterobacteriaceae (ESBL-PE) among participants exposed to, compared to those not exposed to, antimicrobials 
during travel 
 
Definitions: OR odds ratio, CI confidence intervals.  
NOTE: Weights are from random effects analysis

























































Table 2: Summary effect measures, with 95% confidence intervals and measures of heterogeneity, for odds of 
acquiring extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) during travel, with exposure to 
specific classes of antimicrobials during travel across all included studies1 
Antimicrobial class Odds ratio, ESBL-PE 
acquisition (95% 
Confidence Interval)2 
P value for chi-squared test 
of heterogeneity from RE 
model (Cochran’s Q) 
I2 statistic 
(variation in the OR 
attributable to heterogeneity) 
Beta lactam3 1.57 (0.86, 2.87) 0.097 37.8% 
Fluoroquinolone3 4.68 (2.34, 9.37) 0.149 31.3% 
Macrolide4 0.64 (0.17, 2.43) 0.030 57.0% 
Tetracycline (doxycycline)3 1.68 (1.03, 2.72) 0.890 0.0% 
Any antimicrobials5 2.37 (1.69, 3.33) 0.004 56.8% 
1From random effects model 
2Baseline category is to participants with no antimicrobial exposures during travel 
3In all studies, doxycycline was the only tetracycline reported, most frequently for malaria prophylaxis. 4 studies were 
excluded from this analysis.  
48 studies were excluded from this analysis: 4 studies provided no data on rates of ESBL-PE acquisition by macrolide 
exposure, 4 studies reported no macrolide exposure among participants. 
5Tetracyclines included here as antimicrobial exposure, in all but 2 studies for which doxycycline was excluded from 
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